Idelalisib for Previously Treated CLL
Jeffrey Jones, MD, MPH, assistant professor, Internal Medicine, section head, Chronic Lymphocytic Leukemia (CLL) research program, Ohio State University, discusses idelalisib (Zydelig) for previously treated CLL.
Jones says that idelalisib has been studied most extensively in combination with monoclonal antibodies, or in combination with chemotherapy. He and his team have been prescribing the drug since its approval, but with kinase inhibitors, sustained remissions will require continued therapy. This produces consequences for patients' health long term and financial health long term.
Jones and his colleagues are interested in rational combinations that can result in higher response rates and allow discontinuation therapy.
Jeffrey Jones, MD, MPH, assistant professor, Internal Medicine, section head, Chronic Lymphocytic Leukemia (CLL) research program, Ohio State University, discusses idelalisib (Zydelig) for previously treated CLL.
Considering the Durability of Zanubrutinib in Relapsed/Refractory CLL
April 11th 2024During a Case-Based Roundtable® event, Marc S. Hoffmann, MD, discussed his viewpoints on the use of Bruton tyrosine kinase inhibitors for patients with relapsed/refractory chronic lymphocytic leukemia and the efficacy behind zanubrutinib in the second article of a 2-part series.
Read More
